A European Action Plan on Rare Diseases Is a Necessity, Not an Option – EPODIN
European Patients Organization for Dysimmune and Inflammatory Neuropathies (EPODIN) shared a post on LinkedIn:
“A European Action Plan on Rare Diseases: a necessity, not an option
Between 27 and 36 million people in the European Union live with a rare disease.
95% of rare diseases lack of approved therapy.
Diagnostic delays often last years.
- Access to care and therapies still depends heavily on where a patient lives.
- In this context, the European Parliament is working on a European Action Plan on Rare Diseases.
Why does the European level matter?
- Because rare diseases are, by definition, scattered.
- Because expertise is limited and unevenly distributed.
- Because data remain fragmented.
- Because purely national responses have clear limitations.
European added value is not theoretical. It already exists.
The European Reference Networks (ERNs) are a concrete example:
- More than 1,600 centres of expertise connected across Europe
- Virtual cross-border consultations for complex cases
- Shared clinical expertise
- Reduced duplication and improved access to specialised care
ERNs demonstrate that when Europe coordinates and structures expertise, patients benefit from more equitable and timely access to highly specialised care.
However, a future Action Plan will only succeed if patient organisations are placed at the heart of the system.
They are not just stakeholders. They are:
- Identifiers of unmet needs
- Holders of lived expertise
- Partners in research and data generation
- Advocates for equity and non-discrimination
A European rare disease framework is not only about technical coordination.
It is about responding to citizen-driven public health and equity challenges.
Any Action Plan must first and foremost:
- Address transversal unmet needs
- Reduce territorial and social inequalities
- Strengthen structures that already demonstrate clear added value
- Embed the patient voice structurally, not symbolically
Rare diseases are a medical challenge.
They are also a test for Europe’s commitment to health equity and social cohesion.
The response must be collective, coordinated and ambitious.”
Stay updated with Hemostasis Today.
-
Apr 12, 2026, 22:12Maciej Banach: The ‘Metastatic’ Cardiovascular Threat We Can No Longer Ignore
-
Apr 12, 2026, 21:52Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
-
Apr 12, 2026, 21:37Demosthenes Panagiotakos: Hellenic Atherosclerosis Society Calls for Papers on Innovative Strategies in Atherosclerotic Plaque Management
-
Apr 12, 2026, 21:24Heghine Khachatryan: Diagnosing PNH in Resource-Limited Settings
-
Apr 12, 2026, 21:15Katariina Öörni: Role of Cholesterol Absorption Efficiency in Atherosclerosis
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
-
Apr 12, 2026, 17:33Augustina Isioma Ikusemoro: ABO Typing Is Not the Same in Infants and Adults
-
Apr 12, 2026, 17:32Bastu Odoka: Same Blood Group Does Not Guarantee Compatibility
-
Apr 12, 2026, 17:31Jack Hadfield: SARS-CoV-2–Associated Lasting Mitochondrial Injury in Cardiomyocytes